domenica, Dicembre 22, 2024

Kampferolo per la riprogrammazione cellulare nelle allergie: ma con un meccanismo d’azione alternativo

Malattie allergiche come asma, dermatite atopica e allergie alimentari...

Microbiota urinario: il regolatore della formazione dei calcoli renali e possibilmente di altre condizioni

I ricercatori della Cleveland Clinic hanno trovato la prova...

Genomic editing technologies: innovations, applications and ethics

    History and development of genome editing technologies (GETs)

    The idea of ​​directly modifying the genome has deep roots in molecular biology. The first attempts at genetic manipulation date back to the 1970s with the discovery of restriction enzymes, which cut DNA at specific points, and with the development of gene cloning techniques. Genome editing is one of the most revolutionary technologies of the 21st century, opening new frontiers in biology, medicine, agriculture and biotechnology. This technology allows DNA to be modified in a precise manner, allowing direct interventions on the genome to correct genetic mutations, improve the characteristics of plants and animals, and develop new therapies for genetic diseases.

    This article will examine in detail the main genome editing technologies, their potential and current applications, technical challenges and ethical and social implications. Among the most well-known GETs, CRISPR-Cas9 has gained particular attention due to its simplicity, efficiency and versatility. Zinc Finger Nucleases (ZFNs), developed in the 1990s, were one of the first genome editing technologies. These artificial proteins are designed to recognize specific DNA sequences and cut them, allowing for genetic modification. Transcription Activator-Like Effector Nucleases (TALENs), introduced in the early 2000s, are an evolution of ZFNs, are easier to design and offer greater precision in DNA editing.

    The CRISPR-Cas9 Revolution

    The CRISPR-Cas9 system, discovered as part of the adaptive immune system of bacteria, has become the most popular genome editing technology due to its simplicity and efficiency. CRISPR-Cas9 uses a guide RNA (gRNA) to recognize and bind to a specific target DNA sequence. The Cas9 protein acts as a “molecular scissors”, cutting the DNA at the target site. The DNA can then be modified by introducing new sequences or by correcting mutations. CRISPR-Cas9 is less expensive, faster, and easier to use than previous technologies. Its versatility enables a wide range of applications, from editing single genes to engineering entire genomes.

    Next-Generation GETs

    In addition to CRISPR-Cas9, other genome editing technologies have been developed that offer greater precision and new features. CRISPR-Cas12 and Cas13, similar to CRISPR-Cas9, offer additional features, such as the ability to cut RNA or perform more precise edits on DNA. Prime Editing is an innovative technology that uses a modified version of CRISPR to perform genetic modifications without the need to create double-strand breaks in the DNA. This reduces the risk of unwanted mutations and increases the precision of editing. Base Editing, on the other hand, allows one DNA base to be converted into another (for example, C into T) without creating a break in the DNA. This method is particularly useful for correcting point mutations responsible for many genetic diseases.

    Applications of GETs

    One of the most promising areas for genome editing is medicine, where these technologies offer the possibility of treating and potentially curing genetic diseases. Genome editing can be used to correct genetic mutations that are the root cause of inherited diseases such as cystic fibrosis, Duchenne muscular dystrophy, and sickle cell disease. Clinical trials are exploring the use of CRISPR to treat these diseases safely and effectively. Genome editing has been used to engineer T cells, a type of immune cell, to recognize and attack specific types of cancer. This approach, known as CAR-T cell therapy, has shown promise in treating blood cancers. CRISPR-Cas13, which targets RNA, is being developed to treat viral infections such as HIV and hepatitis C by inhibiting viral replication within infected cells.

    Agriculture and Biotechnology

    Genomic editing also has revolutionary potential in agriculture, where it can be used to improve the characteristics of crops and livestock. Genome editing technologies can be used to develop crops that are resistant to disease, drought, and pests, as well as to improve the nutritional value of foods. For example, CRISPR has been used to develop drought-resistant rice varieties and slower-ripening tomatoes. In livestock farming, genome editing can be used to improve animal characteristics, such as disease resistance or efficiency in meat and milk production. One example is the development of pigs resistant to porcine reproductive and respiratory syndrome (PRRS) using CRISPR.

    Precision and off-targeting

    One of the main technical problems with genome editing technologies is the possibility of off-target edits, i.e. unintended mutations in other parts of the genome. Despite continuous improvements, there is always a risk that guide RNA or editing enzymes may bind to and modify DNA sequences that are similar but not identical to the intended target. These off-target edits can cause unwanted and potentially harmful effects. Techniques such as prime editing and base editing have been developed to improve the precision of genome editing and minimize off-target effects. Another challenge is ensuring that genetic changes are stable over time and do not cause long-term adverse effects. In some cases, changes made by genome editing may not be maintained during cell division or may be subject to DNA repair mechanisms that restore the original sequence. In the long term, genetic changes may have unforeseen effects on the health or behavior of cells and organisms, which may only emerge after many years or generations.

    Ethical and social implications

    Genomic editing raises important ethical questions, especially when it involves modifying human DNA. Germline editing, which modifies the DNA of eggs, sperm or embryos, is particularly controversial because the changes can be passed on to future generations. This raises questions about who has the right to make such changes and what the long-term implications are for humanity. Access to genome editing technologies could exacerbate social inequalities, allowing only the wealthiest to benefit from these innovations. There is also a risk that genome editing could be used for non-therapeutic purposes, such as enhancing physical or cognitive abilities, leading to a genetically divided society. Genome editing could have significant effects on the environment, both positive and negative. For example, genome editing also offers opportunities for biodiversity conservation and ecosystem protection, if used carefully and responsibly.

    Future outlook: regulations and standards

    As genome editing technologies rapidly advance, it is essential that regulations and standards keep pace. Harmonized global regulations are needed to ensure that genome editing is used safely and ethically around the world. Public engagement in the genome editing debate is critical to ensure that regulatory decisions reflect society’s values ​​and concerns. With the potential to transform medicine, agriculture, and conservation, these technologies offer unprecedented opportunities to improve human lives and protect the environment. However, it is essential to address the technical challenges and ethical issues associated with genome editing to ensure that these powerful technologies are used safely, equitably, and responsibly.

    • Edited by Dr. Gianfrancesco Cormaci, PhD, specialista in Biochimica Clinica.

    Scientific references

    Rodriguez E, Zhang G et al. (2020). Trends Genet. 36(5), 420-422.

    Anzalone AV, Randolph PB et al. (2019). Nature, 576(7785), 149-157.

    Lander ES, Baylis F et al. (2019). Nature, 567(7747), 165-168.

    Komor AC, Kim YB et al. (2016). Nature, 533(7603), 420-424.

    Doudna JA, Charpentier E. (2014). Science, 346(6213), 1258096.

    Cong L, Ran FA et al. (2013). Science, 339(6121), 819-823.

    Latest

    Newsletter

    Don't miss

    Dott. Gianfrancesco Cormaci
    Dott. Gianfrancesco Cormaci
    Laurea in Medicina e Chirurgia nel 1998; specialista in Biochimica Clinica dal 2002; dottorato in Neurobiologia nel 2006; Ex-ricercatore, ha trascorso 5 anni negli USA (2004-2008) alle dipendenze dell' NIH/NIDA e poi della Johns Hopkins University. Guardia medica presso la casa di Cura Sant'Agata a Catania. Medico penitenziario presso CC.SR. Cavadonna (SR) Si occupa di Medicina Preventiva personalizzata e intolleranze alimentari. Detentore di un brevetto per la fabbricazione di sfarinati gluten-free a partire da regolare farina di grano. Responsabile della sezione R&D della CoFood s.r.l. per la ricerca e sviluppo di nuovi prodotti alimentari, inclusi quelli a fini medici speciali.

    Ospedalizzazioni da COVID e da influenza: il quadro misto del primo inverno post-pandemia con i suoi rischi

    Come il coronavirus SARS-CoV-, i virus influenzali sono virus a RNA avvolti che causano infezioni respiratorie da lievi a gravi. Sia il COVID-19 che...

    Innovazione anticancro: la vitamina C diventa efficace se si toglie il grosso delle calorie

    Dosi farmacologiche di vitamina C (acido ascorbico) sono state proposte come potenziale terapia antitumorale secondo diversi studi preclinici e clinici. Studi recenti indicano che...

    Brain disorders? The solution is always tied to metabolism

    Most of the antidepressant drugs on the market target serotonin or norepinephrine neurotransmitters—chemical messengers in the brain—but these medications don’t work for some people...

    Questo si chiuderà in 20 secondi